CTHRPHA@EC2611A

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

Hanson Pharmaceuticals Transfers Exclusive License of Osteoarthritis Drug to Hengrui

BOC International raises Hengrui Medicine target price to 74 HKD

Citi Gives Hengrui Medicine H Shares 'Buy' Rating with Target Price

UBS Adjusts Hengrui Medicine's Profit Forecast and Maintains Buy Rating

HENGRUI PHARMA released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue HKD 9.229 B (forecast HKD 9.384 B), actual EPS HKD 0 (forecast HKD 0.3986)

Hengrui Medicine reports 21.78% increase in first quarter net profit

Hengrui Medicine's Subsidiary's SHR-A1811 Inclusion in Breakthrough Therapy List

Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS9531 Injection

Hengrui Medicine's Subsidiary's Drug SHR-A2102 Included in Breakthrough Therapy List

Hengrui Medicine's subsidiary receives clinical trial approval for new heart failure drug HRS-7156

HENGRUI PHARMA to Release FY2026 Q1 Earnings on April 22 After-Market (BJT), Forecast Revenue HKD 9.977 B, EPS HKD 0.3984

FAMEGLOW

HAICHANG HLDG

NEW GONOW RV

ZHONGSHENJIANYE

TJCD

INTELLIMARK W27

ZXZN QI-HOUSE

EASYHOLD GROUP

CH CITY INFRA

51WORLD

600276

603259

02359

01276

G Sachs reports that China's healthcare sector has seen muted performance in 2026, with CRO/CDMO segments up 8% YTD. The broker favors visibility-led CDMO companies and selective pharmaceutical investments, focusing on upcoming clinical data. Key players include WUXI APPTEC, HENGRUI PHARMA, and INNOVENT BIO, with significant updates expected at ASCO and ADA meetings. The domestic hospital environment remains weak, prompting a preference for companies with overseas growth potential.

AASTOCKS News

Hengrui Pharma

WuXi AppTec

WUXI APPTEC

HENGRUI PHARMA

Goldman Sachs

INNOVENT BIO

SKB BIO

MircroPort Medbot-B

EDGE MEDICAL-B

ANGELALIGN

GS Hldg R

G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming

Yesterday's closing, HENGRUI PHARMA's Hong Kong stocks traded significantly actively, with a total transaction amount reaching HKD 464 million, which is considered high in the pharmaceutical sector. The stock price has recently been steadily climbing along the 5-day moving average, with the short-term moving average system showing a bullish arrangement. The MACD daily level has initially established a bullish signal, which usually indicates that the buying power is shifting from a wait-and-see approach to actively entering the market, and the momentum for confirming the short-term trend is beginning to strengthen. The volume is relatively ideal, and there are clear signs of a rebound in capital participation enthusiasm. On the news front, the global pharmaceutical industry has recently seen a continuous increase in attention, with Eli Lilly's oral weight loss drug research progress being widely discussed in the market. The GLP-1 sector continues to attract capital inflows, driving expectations for overall valuation recovery in the innovative drug sector. As a leading domestic innovative drug company, HENGRUI PHARMA has multiple research pipelines in critical clinical stages, and the market has high expectations for its overseas progress and commercialization of innovative drugs. Recently, capital inflows into the Hong Kong pharmaceutical sector have significantly accelerated, and the willingness of southbound funds to allocate to high-quality innovative drug targets has increased. The sector's linkage effect provides additional support for individual stock trends. From a technical perspective, HENGRUI PHARMA's current 5-day and 10-day moving averages are both rising, forming the first short-term support. If today's trading volume can maintain above HKD 400 million and stabilize above the short-term moving averages, the probability of challenging the previous range high points is increasing. However, after a continuous strengthening, intraday fluctuations are unavoidable, and if there is a pullback after a peak during the session, attention should be paid to changes in volume and the performance of HENGRUI PHARMA in the A-share market. The short-term trend reference is slightly bullish, with technical aspects and sector sentiment forming a phase resonance, but caution is needed for accumulated profit-taking after consecutive rebounds

Technical Forecast

Eli Lilly

Pre-market trend | HENGRUI PHARMA (1276.HK) on May 13th surged with increased volume leading the pharmaceutical sector, is the bullish momentum about to start?

516500

159859

512290

PILL

159849

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Bristol Myers Squibb

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

E Fund CSI Biotechnology Theme ETF

iShares US Pharma

ALPS Medical Breakthrough

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

ProShares Ultra Health Care ETF

E Fund CSI 300 Health Care ETF

Health Care Select Sector SPDR

Ping An CSI Medicine and Medical Device Innovation ETF

iShares Global Healthcare

Yinhua CSI Innovative Drugs Industry ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Direxion Pharma & Medical Bull 3X

VG Health

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

VanEck Biotech ETF

Bristol-Myers Squibb Company

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

520880

520690

159506

513120

Hengrui Pharmaceutical's shares surged after announcing a USD15.2 billion deal with Bristol Myers Squibb (BMS) to co-develop 13 innovative drugs. Hengrui's stock rose 4.8% in Shanghai and 5.7% in Hong Kong. The agreement grants Hengrui exclusive rights in China, while BMS retains global rights. BMS will pay Hengrui USD950 million upfront, with additional milestone payments, and Hengrui will receive royalties on net sales outside China. The deal awaits regulatory approval and is expected to finalize in Q3 2023, enhancing both companies' drug development capabilities.

Yicai

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS

159102

Jiangsu Hengrui Pharmaceutical has signed a $15.2 billion collaboration and licensing agreement with Bristol Myers Squibb (BMS). Hengrui's shares rose 5.3% in Hong Kong and 4.84% in Shenzhen following the announcement. The deal includes 13 preclinical programs, with BMS paying up to $950 million upfront. This partnership highlights China's growing role in innovative drug development, although experts note the need for further advancements in the pharmaceutical value chain. Hengrui will receive tiered royalties on sales outside mainland China, Hong Kong, and Macau.

SCMP

Huaan Hang Seng Biotech ETF

TIGERMED

Tigermed

上海镁信健康科技集团股份有限公司

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

06656

01766

06869

00857

02513

00100

06288

02476

02338

SIGENERGY(06656) rose 6.7%, with a trading turnover 173.6 Million HKD, and a year-to-date rose 74.3%. HENGRUI PHARMA(01276) rose 4.84%, with a trading turnover 1.4 Billion HKD, and a year-to-date fell 2.5%. KNOWLEDGE ATLAS(02513) fell 6.56%, with a trading turnover 779.8 Million HKD, and a year-to-date rose 622.9%. MINIMAX-W(00100) fell 6.31%, with a trading turnover 881.7 Million HKD, and a year-to-date rose 318.5%.

Top Gainers&Losers

SIGENERGY

CRRC

YOFC

PETROCHINA

KNOWLEDGE ATLAS

MINIMAX-W

FAST RETAIL-DRS

WEICHAI POWER

Top 5 HK Stock Gainers/Losers (>100B) (5.12)

The US imposed a 39% tariff on imported gold bars, sparking a rally in gold stocks, with Lao Feng Xiang rising nearly 4% again. The semiconductor sector was dragged down by SMIC's Q2 net profit plunging 19%, with most stocks falling.

SMIC

SMIC HK SDR 5to1

LAOPU GOLD

ZIJIN MINING

Zijin Mining

SD GOLD

SD-GOLD

FORTIOR

Asymchem

ZHAOJIN MINING

HORIZONROBOT-W

LINGBAO GOLD

INNOSCIENCE

CE HUADA TECH

BATELAB

ZAI LAB

Zai Lab

FRONTAGE

CHIFENG GOLD

TONGGUAN GOLD

CHI SILVER GP

HUA HONG SEMI

Hua Hong

Hot Trades in Hong Kong Stocks (8.8)｜Gold Sector Rises Across the Board on Tariff Catalysts, SMIC Leads Decline by 6%

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

3SBIO

CSPC PHARMA

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

CHINA LIFE

China Life

SBP GROUP

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI BIO

WuXi Biologics

REMEGEN

RemeGen

DUALITYBIO-B

INNOCARE

InnoCare Pharma

AKESO

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

ZA ONLINE

POP MART

MIXUE GROUP

GUMING

LIANLIAN

PICC P&C

MAO GEPING

BLOKS

PING AN

Ping An Ins HK SDR2to1

Ping An

Ping An Insurance

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

CTHRPHA@EC2611A(29479.HK)

G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming

Pre-market trend | HENGRUI PHARMA (1276.HK) on May 13th surged with increased volume leading the pharmaceutical sector, is the bullish momentum about to start?

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS